Lmcg Investments LLC Sells 63,413 Shares of Johnson & Johnson (NYSE:JNJ)

Lmcg Investments LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 72.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 23,749 shares of the company’s stock after selling 63,413 shares during the period. Lmcg Investments LLC’s holdings in Johnson & Johnson were worth $3,435,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. Fred Alger Management LLC boosted its holdings in shares of Johnson & Johnson by 6.1% during the 2nd quarter. Fred Alger Management LLC now owns 42,968 shares of the company’s stock worth $6,280,000 after buying an additional 2,488 shares during the period. AQR Capital Management LLC boosted its holdings in Johnson & Johnson by 38.6% in the 2nd quarter. AQR Capital Management LLC now owns 3,350,292 shares of the company’s stock valued at $489,176,000 after purchasing an additional 932,477 shares during the period. Ameriprise Financial Inc. boosted its holdings in Johnson & Johnson by 5.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 14,374,397 shares of the company’s stock valued at $2,100,427,000 after purchasing an additional 754,200 shares during the period. Drucker Wealth 3.0 LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at about $612,000. Finally, Daymark Wealth Partners LLC boosted its holdings in Johnson & Johnson by 2.0% in the 2nd quarter. Daymark Wealth Partners LLC now owns 304,204 shares of the company’s stock valued at $44,462,000 after purchasing an additional 6,033 shares during the period. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on JNJ. Leerink Partners cut their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday. Stifel Nicolaus cut their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday. Raymond James cut their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Morgan Stanley dropped their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday. Nine investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $170.06.

Insider Activity

In related news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.9 %

Shares of NYSE JNJ opened at $146.58 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The firm has a 50 day moving average price of $148.10 and a two-hundred day moving average price of $156.05. The stock has a market cap of $352.91 billion, a P/E ratio of 21.21, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22,438,500 billion. During the same period in the prior year, the firm posted $2.29 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 9.95 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.